# Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

> **NCT06532591** · PHASE2 · RECRUITING · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin

## Key facts

- **NCT ID:** NCT06532591
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532591, "Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06532591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*